Also trades as: PFE.TO (TSX) · $vol 1M · PFE.F (FSX) · $vol 1M · PFE.DE (XETRA) · $vol 1M · PFE.NE (NEO) · $vol 1M · PFE.BA (BUE) · $vol 0M
PFE NYSE
Pfizer Inc.
1W: +1.2%
1M: +3.9%
3M: +18.0%
YTD: +20.3%
1Y: +22.9%
3Y: +10.2%
5Y: -10.7%
$29.73
-0.06 (-0.20%)
Weekly Expected Move ±2.9%
$28
$29
$30
$31
$32
Credit Risk of going bust: lower than 82% of companies Debt: 27.1% of company value Bonds: $1.15B held by 485 funds, 62 bp over Treasuries → details ▾
Of US companies ranked in the safest four tenths, about 1 in 3,500 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.54 (down 98%), Pfizer Inc. would be worth roughly what it owes.
Total debt $63.19B against a stock market value of $169.79B.
Distance to default 10.27 (Merton model): prices to 2026-10-26, balance sheet 2026-06-28, debt counted $32.95B (short-term plus half of long-term), stock volatility 21.2%; Altman Z 2.14. A ranking and a back-test, not a forecast.
Bond figures are fund-reported marks (SEC N-PORT) as of Jul 2026. How these are computed.
If the stock fell to about $0.54 (down 98%), Pfizer Inc. would be worth roughly what it owes.
Total debt $63.19B against a stock market value of $169.79B.
Distance to default 10.27 (Merton model): prices to 2026-10-26, balance sheet 2026-06-28, debt counted $32.95B (short-term plus half of long-term), stock volatility 21.2%; Altman Z 2.14. A ranking and a back-test, not a forecast.
Bond figures are fund-reported marks (SEC N-PORT) as of Jul 2026. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
#10
of 19
Drug Manufacturers - General
Technical Signal Map
18 Bullish
2 Neutral
3 Bearish
PFE
$171B
Pfizer Inc.
BULLISH
+91
ORINY
$30B
Orion Oyj
BULLISH
+100
ABBV
$505B
AbbVie Inc.
BULLISH
+91
OTSKY
$42B
Otsuka Holdings Co., Ltd.
BULLISH
+91
SNY
$100B
Sanofi
BULLISH
+84
CHGCF
$74B
Chugai Pharmaceutical Co., Ltd.
BULLISH
+84
RHHBF
$393B
Roche Holding AG
BULLISH
+75
NVS
$287B
Novartis AG
BULLISH
+75
BIIB
$37B
Biogen Inc.
BULLISH
+75
LLY
$1.2T
Eli Lilly and Company
BULLISH
+66
AMGN
$237B
Amgen Inc.
BULLISH
+66
GSK
$102B
GSK plc
BULLISH
+59
AZN
$266B
AstraZeneca PLC
BULLISH
+50
GILD
$193B
Gilead Sciences, Inc.
BULLISH
+50
DSNKY
$33B
Daiichi Sankyo Company, Limited
BULLISH
+50
JNJ
$636B
Johnson & Johnson
BULLISH
+43
ALPMF
$30B
Astellas Pharma Inc.
BULLISH
+32
BMY
$126B
Bristol-Myers Squibb Company
LEAN BULL
+16
CHJTF
$14B
CSPC Pharmaceutical Group Limited
NEUTRAL
+1
NONOF
$172B
Novo Nordisk A/S
NEUTRAL
-2
BAYRY
$48B
Bayer AG
BEARISH
-40
MRK
$358B
Merck & Co., Inc.
BEARISH
-68
GIKLY
$15B
Grifols, S.A.
BEARISH
-91
Peer Comparison
| Symbol | Mkt Cap | P/E | ROE % | ROIC % | Net Mgn % | Rev Grw % | Piotroski | Signal | 1Y Ret % |
|---|---|---|---|---|---|---|---|---|---|
| PFE Pfizer Inc. | $171B | 39.3 | 5.0 | 11.3 | -1.6 | -0.2 | 7 | BULLISH | 22.9 |
| ORINY Orion Oyj | $30B | 23.1 | 53.6 | 46.3 | 26.9 | 22.6 | 7 | BULLISH | 46.8 |
| ABBV AbbVie Inc. | $505B | 80.5 | -206.4 | 23.5 | 21.3 | 10.4 | 7 | BULLISH | 25.7 |
| OTSKY Otsuka Holdings Co., Ltd. | $42B | 16.0 | 13.8 | 12.2 | 16.7 | 10.9 | 8 | BULLISH | 45.1 |
| SNY Sanofi | $100B | 23.0 | 5.7 | 6.4 | 2.8 | 13.4 | 6 | BULLISH | -15.6 |
| CHGCF Chugai Pharmaceutical Co., Ltd. | $74B | 23.3 | 23.7 | 45.1 | 34.1 | 12.6 | 6 | BULLISH | 1.2 |
| RHHBF Roche Holding AG | $393B | 25.8 | 40.2 | 24.6 | 22.6 | 27.8 | 6 | BULLISH | 30.5 |
| NVS Novartis AG | $287B | 23.6 | 30.6 | 16.8 | 22.7 | 0.8 | 5 | BULLISH | 16.8 |
| BIIB Biogen Inc. | $37B | 44.2 | 4.6 | 4.8 | 3.6 | -0.5 | 3 | BULLISH | 68.1 |
| LLY Eli Lilly and Company | $1.2T | 43.0 | 102.4 | 39.2 | 30.9 | 49.6 | 9 | BULLISH | 56.0 |
| AMGN Amgen Inc. | $237B | 27.4 | 91.5 | 19.5 | 23.6 | 9.2 | 8 | BULLISH | 56.0 |
| GSK GSK plc | $102B | 16.0 | 25.5 | 18.8 | 5.2 | 5.0 | 7 | BULLISH | 13.2 |
| AZN AstraZeneca PLC | $266B | 25.4 | 22.0 | 15.0 | 16.3 | 8.6 | 9 | BULLISH | 3.0 |
| GILD Gilead Sciences, Inc. | $193B | -60.6 | -20.6 | -3.4 | -134.5 | 5.5 | 5 | BULLISH | 32.3 |
| DSNKY Daiichi Sankyo Company, Limited | $33B | 19.6 | 15.1 | 12.5 | 11.9 | 17.4 | 5 | BULLISH | -33.2 |
| JNJ Johnson & Johnson | $636B | 40.5 | 20.0 | 21.3 | 0.8 | 7.8 | 6 | BULLISH | 39.2 |
| ALPMF Astellas Pharma Inc. | $30B | 12.4 | 21.4 | 16.9 | 22.1 | 17.3 | 7 | BULLISH | 65.7 |
| BMY Bristol-Myers Squibb Company | $126B | 13.5 | 46.7 | 17.8 | 25.6 | 3.1 | 8 | LEAN BULL | 46.8 |
| CHJTF CSPC Pharmaceutical Group Limited | $14B | 10.3 | 20.7 | 36.7 | 32.8 | 88.1 | 6 | NEUTRAL | 13.3 |
| NONOF Novo Nordisk A/S | $172B | 9.9 | 59.8 | 35.2 | 26.7 | 5.6 | 5 | NEUTRAL | -28.1 |
| BAYRY Bayer AG | $48B | -25.8 | -5.5 | 6.4 | 2.0 | -1.5 | 4 | BEARISH | 59.4 |
| MRK Merck & Co., Inc. | $358B | 112.0 | 7.0 | 6.1 | -8.0 | 4.5 | 4 | BEARISH | 62.7 |
| GIKLY Grifols, S.A. | $15B | 15.9 | 8.4 | 7.4 | 8.2 | -0.2 | 6 | BEARISH | -19.0 |
| PFE Pfizer Inc. | $171B | 39.3 | 5.0 | 11.3 | -1.6 | -0.2 | 7 | BULLISH | 22.9 |
| MDT Medtronic Plc | $122B | 23.0 | 10.7 | 7.8 | 15.1 | 9.8 | 9 | BULLISH | 4.0 |
| DHR Danaher Corporation | $162B | 37.9 | 8.3 | 6.3 | 18.8 | 5.5 | 7 | BULLISH | 5.4 |
| CVS CVS Health Corp. | $120B | 24.2 | 6.2 | 4.9 | 2.8 | 7.4 | 8 | BULLISH | 14.1 |
| MCK McKesson Corporation | $117B | 26.2 | -148.0 | 237.7 | 0.6 | 8.8 | 8 | BULLISH | 25.3 |
| ELV Elevance Health Inc. | $95B | 18.2 | 11.6 | 16.2 | 2.7 | 3.6 | 7 | BULLISH | 25.2 |
| REGN Regeneron Pharmaceuticals, Inc. | $83B | 19.4 | 14.0 | 12.9 | 30.2 | 9.3 | 7 | BULLISH | 40.5 |
| CI Cigna Corporation | $81B | 12.5 | 15.5 | 11.8 | 2.3 | 7.7 | 8 | BULLISH | 0.9 |
| HCA HCA Healthcare, Inc. | $102B | 54.8 | -124.7 | 23.3 | 8.4 | 7.3 | 6 | BULLISH | 5.7 |
| ABT Abbott Laboratories | $179B | 38.3 | 10.7 | 7.3 | 7.4 | 8.1 | 5 | BULLISH | -17.0 |
| ISRG Intuitive Surgical, Inc. | $160B | 53.8 | 18.0 | 22.6 | 17.1 | 20.5 | 7 | BULLISH | -18.1 |
| SYK Stryker Corporation | $118B | 30.8 | 16.5 | 11.6 | 19.4 | 8.5 | 9 | BULLISH | -20.0 |
| TMO Thermo Fisher Scientific Inc. | $249B | 36.2 | 13.4 | 8.6 | 14.2 | 8.3 | 8 | BULLISH | 19.8 |
| ESLOF EssilorLuxottica S.A. | $94B | 33.2 | 6.5 | 5.2 | 10.6 | 7.4 | 6 | BULLISH | -44.7 |
| SOAGY Sartorius AG ADR | $92B | 90.9 | 7.7 | 6.6 | 7.1 | 4.3 | 7 | BULLISH | 18.0 |
| MKGAF Merck KGaA | $70B | 26.1 | 8.1 | 8.1 | 9.0 | -0.4 | 7 | BULLISH | 24.1 |
| CSLLY CSL Limited | $134B | -26.2 | -15.2 | 13.1 | -40.2 | 1.7 | 4 | BULLISH | -1.5 |
| FSNUY Fresenius SE & Co. KGaA | $117B | 16.8 | 8.1 | 5.6 | 6.4 | 5.9 | 7 | BULLISH | -18.2 |
| VRTX Vertex Pharmaceuticals Incorporated | $133B | 29.7 | 23.5 | 28.3 | 33.0 | 10.6 | 6 | BULLISH | 22.4 |
| SRTOY Sartorius Stedim Biotech S.A. | $228B | 64.8 | 7.4 | 6.2 | 12.5 | 4.4 | 8 | BULLISH | -1.8 |
| MRNA Moderna, Inc. | $80B | -23.4 | -39.0 | -90.1 | -539.3 | -27.2 | 2 | LEAN BEAR | 681.3 |
| PFE Pfizer Inc. | $171B | 39.3 | 5.0 | 11.3 | -1.6 | -0.2 | 7 | BULLISH | 22.9 |
| MDT Medtronic Plc | $122B | 23.0 | 10.7 | 7.8 | 15.1 | 9.8 | 9 | BULLISH | 4.0 |
| LZAGY Lonza Group AG | $54B | -409.1 | 13.5 | 10.5 | 17.5 | -9.7 | 8 | BULLISH | 6.2 |
| ORINY Orion Oyj | $30B | 23.1 | 53.6 | 46.3 | 26.9 | 22.6 | 7 | BULLISH | 46.8 |
| RPRX Royalty Pharma plc | $28B | 26.9 | 12.4 | 10.6 | 2.7 | 10.0 | 6 | BULLISH | 76.7 |
| LH Labcorp Holdings Inc. | $27B | 26.9 | 11.7 | 8.6 | 8.0 | 6.4 | 8 | BULLISH | 17.4 |
| ZBH Zimmer Biomet Holdings, Inc. | $19B | 23.2 | 6.4 | 5.9 | 9.1 | 8.6 | 6 | BULLISH | -5.5 |
| MEDP Medpace Holdings, Inc. | $19B | 36.7 | 117.9 | 1953.7 | 19.2 | 20.4 | 9 | BULLISH | 13.4 |
| CRL Charles River Laboratories International, Inc. | $17B | -73.3 | -7.7 | 6.9 | -0.1 | -0.7 | 4 | BULLISH | 87.0 |
| HALO Halozyme Therapeutics, Inc. | $14B | 36.0 | 173.7 | 32.5 | 47.8 | 41.2 | 5 | BULLISH | 91.4 |
| QGEN Qiagen N.V. | $10B | 25.8 | 11.9 | 11.2 | 19.3 | 3.0 | 8 | BULLISH | 2.1 |
| ABBV AbbVie Inc. | $505B | 80.5 | -206.4 | 23.5 | 21.3 | 10.4 | 7 | BULLISH | 25.7 |
| DHR Danaher Corporation | $162B | 37.9 | 8.3 | 6.3 | 18.8 | 5.5 | 7 | BULLISH | 5.4 |
| CVS CVS Health Corp. | $120B | 24.2 | 6.2 | 4.9 | 2.8 | 7.4 | 8 | BULLISH | 14.1 |
| MCK McKesson Corporation | $117B | 26.2 | -148.0 | 237.7 | 0.6 | 8.8 | 8 | BULLISH | 25.3 |
| ELV Elevance Health Inc. | $95B | 18.2 | 11.6 | 16.2 | 2.7 | 3.6 | 7 | BULLISH | 25.2 |
| REGN Regeneron Pharmaceuticals, Inc. | $83B | 19.4 | 14.0 | 12.9 | 30.2 | 9.3 | 7 | BULLISH | 40.5 |
| CI Cigna Corporation | $81B | 12.5 | 15.5 | 11.8 | 2.3 | 7.7 | 8 | BULLISH | 0.9 |
| TKPHF Takeda Pharmaceutical Company Limited | $66B | 56.1 | 2.5 | 2.8 | 9.3 | 3.3 | 6 | BULLISH | 41.9 |
| CAH Cardinal Health, Inc. | $58B | 34.3 | -60.5 | 92.8 | 0.6 | 14.2 | 8 | BULLISH | 59.6 |
| BDX Becton, Dickinson and Company | $54B | 58.7 | 3.8 | 4.1 | 7.6 | -2.6 | 6 | BULLISH | 5.9 |
| SDZNY Sandoz Group AG | $42B | 66.7 | 7.2 | 10.1 | 1.9 | 29.1 | 6 | BULLISH | 60.0 |
| OTSKY Otsuka Holdings Co., Ltd. | $42B | 16.0 | 13.8 | 12.2 | 16.7 | 10.9 | 8 | BULLISH | 45.1 |
| ONC BeOne Medicines AG | $40B | 25.2 | 14.7 | 57.2 | 13.9 | 34.3 | 8 | BULLISH | 19.6 |
| CNC Centene Corp. | $35B | 23.8 | 6.8 | 6.4 | -0.1 | 4.8 | 8 | BULLISH | 98.1 |
| MTD Mettler-Toledo International Inc. | $33B | 37.5 | -736.4 | 46.7 | 22.7 | 6.9 | 8 | BULLISH | 16.2 |
| WST West Pharmaceutical Services, Inc. | $28B | 50.0 | 19.1 | 19.0 | 17.7 | 12.4 | 9 | BULLISH | 28.6 |
| EXEL Exelixis, Inc. | $16B | 19.7 | 44.4 | 69.0 | 33.7 | 9.2 | 8 | BULLISH | 71.1 |
| ICLR ICON Public Limited Company | $14B | 42.7 | 3.5 | 5.5 | 3.5 | 2.0 | 6 | BULLISH | 2.1 |
| PMCUF Pro Medicus Limited | $13B | 78.1 | 75.0 | 68.1 | 68.7 | 22.8 | 7 | BULLISH | -30.9 |
| AVTR Avantor, Inc. | $12B | -20.5 | -9.7 | -2.5 | 2.3 | -1.6 | 6 | BULLISH | 11.8 |
| GKOS Glaukos Corporation | $11B | -56.6 | -26.0 | -12.7 | -9.9 | 41.5 | 3 | BULLISH | 137.1 |
| HCA HCA Healthcare, Inc. | $102B | 54.8 | -124.7 | 23.3 | 8.4 | 7.3 | 6 | BULLISH | 5.7 |
| IDXX IDEXX Laboratories, Inc. | $44B | 39.5 | 74.2 | 46.5 | 27.8 | 12.8 | 9 | BULLISH | -10.7 |
| GEHC GE HealthCare Technologies Inc. | $32B | 20.2 | 15.4 | 10.6 | 10.8 | 1.4 | 5 | BULLISH | -6.8 |
| CLPBY Coloplast A/S | $17B | 38.5 | 18.5 | 70.9 | 19.9 | -2.9 | 5 | BULLISH | -21.7 |
| ASND Ascendis Pharma A/S | $15B | 18.1 | 121.1 | 76.2 | 61.0 | 114.8 | 7 | BULLISH | 22.0 |
| PEN Penumbra, Inc. | $13B | 79.4 | 11.4 | 13.6 | 8.9 | 17.6 | 6 | BULLISH | 28.3 |
| ABT Abbott Laboratories | $179B | 38.3 | 10.7 | 7.3 | 7.4 | 8.1 | 5 | BULLISH | -17.0 |
| ISRG Intuitive Surgical, Inc. | $160B | 53.8 | 18.0 | 22.6 | 17.1 | 20.5 | 7 | BULLISH | -18.1 |
| SYK Stryker Corporation | $118B | 30.8 | 16.5 | 11.6 | 19.4 | 8.5 | 9 | BULLISH | -20.0 |
| SNY Sanofi | $100B | 23.0 | 5.7 | 6.4 | 2.8 | 13.4 | 6 | BULLISH | -15.6 |
| CHGCF Chugai Pharmaceutical Co., Ltd. | $74B | 23.3 | 23.7 | 45.1 | 34.1 | 12.6 | 6 | BULLISH | 1.2 |
| BSX Boston Scientific Corporation | $66B | 18.1 | 15.5 | 11.6 | 16.7 | 13.5 | 8 | BULLISH | -55.5 |
| UTHR United Therapeutics Corporation | $25B | 19.3 | 19.3 | 31.3 | 42.5 | 2.5 | 6 | BULLISH | 39.1 |
| PODD Insulet Corp. | $10B | 27.6 | 26.0 | 21.3 | 11.8 | 29.4 | 9 | BULLISH | -53.9 |
| TMO Thermo Fisher Scientific Inc. | $249B | 36.2 | 13.4 | 8.6 | 14.2 | 8.3 | 8 | BULLISH | 19.8 |
| WILYY Demant A/S | $12B | 46.7 | 15.9 | 10.9 | 9.1 | 10.6 | 5 | BULLISH | 47.3 |
| HLN Haleon plc | $45B | 20.7 | 10.1 | 8.4 | 13.6 | 1.3 | 8 | BULLISH | 8.9 |
| ZTS Zoetis Inc. | $33B | 13.0 | 64.4 | 26.3 | 28.0 | 1.4 | 6 | BULLISH | -44.5 |
| PHG Koninklijke Philips N.V. | $26B | 20.3 | 10.2 | 7.6 | 8.8 | -1.1 | 6 | BULLISH | -8.4 |
| SNN Smith & Nephew plc | $13B | 19.8 | 11.8 | 9.9 | 9.8 | 5.3 | 7 | BULLISH | -14.2 |
| COO The Cooper Companies, Inc. | $12B | 20.4 | 6.8 | 6.3 | 40.6 | 4.7 | 6 | BULLISH | -17.9 |
| RHHBF Roche Holding AG | $393B | 25.8 | 40.2 | 24.6 | 22.6 | 27.8 | 6 | BULLISH | 30.5 |
| NVS Novartis AG | $287B | 23.6 | 30.6 | 16.8 | 22.7 | 0.8 | 5 | BULLISH | 16.8 |
| ESLOF EssilorLuxottica S.A. | $94B | 33.2 | 6.5 | 5.2 | 10.6 | 7.4 | 6 | BULLISH | -44.7 |
| SOAGY Sartorius AG ADR | $92B | 90.9 | 7.7 | 6.6 | 7.1 | 4.3 | 7 | BULLISH | 18.0 |
| EW Edwards Lifesciences Corporation | $51B | 51.7 | 9.5 | 17.9 | 13.9 | 14.6 | 6 | BULLISH | 18.3 |
| BIIB Biogen Inc. | $37B | 44.2 | 4.6 | 4.8 | 3.6 | -0.5 | 3 | BULLISH | 68.1 |
| TRUMY Terumo Corporation | $22B | 21.5 | 11.0 | 9.6 | 22.6 | 15.6 | 5 | BULLISH | -8.5 |
| ALGN Align Technology, Inc. | $11B | 26.3 | 10.2 | 12.3 | 10.3 | 4.4 | 7 | BULLISH | 12.0 |
| NTRA Natera, Inc. | $58B | -297.1 | -12.5 | -23.6 | -8.9 | 37.8 | 6 | BULLISH | 107.6 |
| LLY Eli Lilly and Company | $1.2T | 43.0 | 102.4 | 39.2 | 30.9 | 49.6 | 9 | BULLISH | 56.0 |
| AMGN Amgen Inc. | $237B | 27.4 | 91.5 | 19.5 | 23.6 | 9.2 | 8 | BULLISH | 56.0 |
| MKGAF Merck KGaA | $70B | 26.1 | 8.1 | 8.1 | 9.0 | -0.4 | 7 | BULLISH | 24.1 |
| COR Cencora, Inc. | $63B | 24.2 | 104.3 | 26.5 | 0.9 | 5.1 | 7 | BULLISH | 0.7 |
| IQV IQVIA Holdings Inc. | $46B | 33.0 | 21.7 | 33.3 | 7.9 | 8.8 | 9 | BULLISH | 24.4 |
| WAT Waters Corporation | $45B | 114.0 | 1.9 | 1.5 | -8.3 | 52.5 | 5 | BULLISH | 28.2 |
| GNMSF Genmab A/S | $28B | 34.9 | 3.9 | 11.9 | 26.2 | -82.1 | 4 | BULLISH | 50.6 |
| SONVF Sonova Holding AG | $20B | 38.9 | 20.4 | 17.2 | 19.7 | -7.1 | 6 | BULLISH | 22.9 |
| BAX Baxter International Inc. | $13B | -12.2 | -15.7 | -1.6 | 4.3 | 5.4 | 3 | BULLISH | 10.2 |
| UCBJY UCB S.A. | $58B | 23.3 | 20.7 | 16.4 | 26.0 | 25.3 | 6 | BULLISH | 5.3 |
| ALC Alcon Inc. | $34B | 53.5 | 2.9 | 3.6 | 0.0 | 7.8 | 6 | BULLISH | -8.2 |
| STE STERIS plc | $23B | 27.9 | 11.4 | 9.7 | 13.4 | 8.4 | 8 | BULLISH | -4.6 |
| GSK GSK plc | $102B | 16.0 | 25.5 | 18.8 | 5.2 | 5.0 | 7 | BULLISH | 13.2 |
| SEMHF Siemens Healthineers AG | $53B | 21.2 | 12.1 | 8.4 | 11.6 | 10.0 | 9 | BULLISH | -17.7 |
| DGX Quest Diagnostics Incorporated | $27B | 23.6 | 15.2 | 10.2 | 10.1 | 9.1 | 8 | BULLISH | 32.6 |
| SAUHY Straumann Holding AG | $19B | 41.8 | 17.3 | 21.7 | 18.1 | 3.0 | 6 | BULLISH | 5.1 |
| NBIX Neurocrine Biosciences, Inc. | $15B | 20.6 | 22.1 | 16.0 | 15.1 | 34.4 | 6 | BULLISH | 1.5 |
| GMED Globus Medical, Inc. | $11B | 20.2 | 11.8 | 12.3 | 19.2 | 19.7 | 8 | BULLISH | 30.2 |
| CSLLY CSL Limited | $134B | -26.2 | -15.2 | 13.1 | -40.2 | 1.7 | 4 | BULLISH | -1.5 |
| RVTY Revvity, Inc. | $18B | 76.0 | 3.2 | 3.5 | 7.1 | 5.5 | 6 | BULLISH | 64.4 |
| TECH Bio-Techne Corporation | $11B | 62.1 | 9.0 | 8.9 | 17.0 | -0.4 | 7 | BULLISH | 10.2 |
| MOH Molina Healthcare, Inc. | $11B | -329.7 | -1.2 | -44.2 | 0.4 | -2.1 | 5 | BULLISH | 27.3 |
| IPSEY Ipsen S.A. | $58B | 24.4 | 11.5 | 16.3 | 18.2 | 8.0 | 6 | BULLISH | 25.4 |
| AZN AstraZeneca PLC | $266B | 25.4 | 22.0 | 15.0 | 16.3 | 8.6 | 9 | BULLISH | 3.0 |
| GILD Gilead Sciences, Inc. | $193B | -60.6 | -20.6 | -3.4 | -134.5 | 5.5 | 5 | BULLISH | 32.3 |
| DSNKY Daiichi Sankyo Company, Limited | $33B | 19.6 | 15.1 | 12.5 | 11.9 | 17.4 | 5 | BULLISH | -33.2 |
| ROIV Roivant Sciences Ltd. | $26B | -95.0 | -6.2 | -217.5 | -13164.4 | -67.6 | 1 | BULLISH | 99.0 |
| VTRS Viatris Inc. | $21B | -51.7 | -2.8 | -0.3 | -3.2 | 4.4 | 7 | BULLISH | 79.5 |
| BMXXY bioMérieux S.A. | $12B | 22.6 | 11.2 | 8.9 | 11.5 | -3.5 | 7 | BULLISH | -28.0 |
| DVA DaVita Inc. | $12B | 15.7 | -149.4 | 17.9 | 7.5 | 6.4 | 8 | BULLISH | 43.8 |
| UHS Universal Health Services, Inc. | $11B | 7.2 | 21.0 | 12.5 | 7.7 | 10.0 | 8 | BULLISH | -10.8 |
| RDY Dr. Reddy's Laboratories Limited | $11B | 39.0 | 7.5 | 6.0 | 10.7 | -3.1 | 4 | BULLISH | -5.9 |
| HUM Humana Inc. | $51B | 39.2 | 6.8 | 17.2 | 1.7 | 18.3 | 4 | BULLISH | 43.1 |
| RCDTF Recordati Industria Chimica e Farmaceutica S.p.A. | $12B | 21.8 | 24.9 | 15.4 | 16.7 | 9.2 | 7 | BULLISH | -9.2 |
| JNJ Johnson & Johnson | $636B | 40.5 | 20.0 | 21.3 | 0.8 | 7.8 | 6 | BULLISH | 39.2 |
| FSNUY Fresenius SE & Co. KGaA | $117B | 16.8 | 8.1 | 5.6 | 6.4 | 5.9 | 7 | BULLISH | -18.2 |
| ENSG The Ensign Group, Inc. | $10B | 26.2 | 17.0 | 8.1 | 6.9 | 18.9 | 7 | BULLISH | -4.6 |
| THC Tenet Healthcare Corporation | $22B | 9.8 | 53.3 | 19.1 | 14.7 | 5.4 | 7 | BULLISH | 30.0 |
| UNH UnitedHealth Group Incorporated | $375B | 23.5 | 15.9 | 13.5 | 3.6 | 3.3 | 7 | BULLISH | 14.7 |
| ERFSF Eurofins Scientific SE | $17B | 28.5 | 12.8 | 4.6 | 8.2 | 3.3 | 6 | BULLISH | 33.0 |
| FSPKF Fisher & Paykel Healthcare Corporation Limited | $16B | 60.2 | 23.3 | 27.3 | 20.6 | 5.0 | 6 | BULLISH | 45.1 |
| EHC Encompass Health Corporation | $12B | 19.5 | 25.5 | 16.7 | 9.6 | 9.5 | 9 | BULLISH | -1.8 |
| VRTX Vertex Pharmaceuticals Incorporated | $133B | 29.7 | 23.5 | 28.3 | 33.0 | 10.6 | 6 | BULLISH | 22.4 |
| SGIOY Shionogi & Co., Ltd. | $16B | 9.8 | 13.6 | 9.9 | 50.6 | 10.3 | 5 | BULLISH | 20.9 |
| RGEN Repligen Corporation | $11B | -823.9 | -0.6 | -1.4 | -18.4 | 13.8 | 4 | BULLISH | 9.0 |
| SRTOY Sartorius Stedim Biotech S.A. | $228B | 64.8 | 7.4 | 6.2 | 12.5 | 4.4 | 8 | BULLISH | -1.8 |
| ALPMF Astellas Pharma Inc. | $30B | 12.4 | 21.4 | 16.9 | 22.1 | 17.3 | 7 | BULLISH | 65.7 |
| ILMN Illumina, Inc. | $41B | 51.2 | 32.4 | 18.2 | 17.9 | 4.9 | 7 | LEAN BULL | 171.1 |
| BBIO BridgeBio Pharma, Inc. | $13B | -19.2 | 32.4 | 57.9 | -62.5 | 202.4 | 4 | LEAN BULL | 26.6 |
| A Agilent Technologies, Inc. | $49B | 34.6 | 21.0 | 14.9 | 19.3 | 8.6 | 7 | LEAN BULL | 19.3 |
| HOCPY HOYA Corporation | $56B | 33.4 | 27.3 | 46.1 | 25.7 | 14.2 | 6 | LEAN BULL | 10.1 |
| BMY Bristol-Myers Squibb Company | $126B | 13.5 | 46.7 | 17.8 | 25.6 | 3.1 | 8 | LEAN BULL | 46.8 |
| TEVA Teva Pharmaceutical Industries Limited | $46B | 64.1 | 9.7 | 9.3 | -13.9 | 4.1 | 7 | LEAN BULL | 110.1 |
| BIOVF Swedish Orphan Biovitrum AB | $16B | 115.7 | 3.4 | 17.2 | 14.0 | 13.3 | 4 | LEAN BULL | 37.3 |
| GH Guardant Health, Inc. | $23B | -49.9 | 171.6 | -88.3 | -35.9 | 42.7 | 6 | LEAN BULL | 149.8 |
| FMS Fresenius Medical Care AG & Co. KGaA | $12B | 12.2 | 7.3 | 6.7 | 4.5 | -0.5 | 7 | NEUTRAL | -15.4 |
| AAVXF Abivax S.A. | $12B | -16.7 | -221.8 | 440.6 | — | -133.5 | 4 | NEUTRAL | 57.0 |
| JDHIY JD Health International Inc. | $16B | 16.4 | 10.3 | 31.0 | 8.4 | 19.6 | 6 | NEUTRAL | -43.9 |
| CHJTF CSPC Pharmaceutical Group Limited | $14B | 10.3 | 20.7 | 36.7 | 32.8 | 88.1 | 6 | NEUTRAL | 13.3 |
| NONOF Novo Nordisk A/S | $172B | 9.9 | 59.8 | 35.2 | 26.7 | 5.6 | 5 | NEUTRAL | -28.1 |
| IHHHF IHH Healthcare Berhad | $15B | 30.9 | 7.3 | 6.1 | 8.1 | 7.1 | 5 | NEUTRAL | 43.7 |
| BTSG BrightSpring Health Services, Inc. Common Stock | $12B | 41.0 | 15.5 | 10.3 | 2.2 | 19.9 | 7 | LEAN BEAR | 75.8 |
| MRNA Moderna, Inc. | $80B | -23.4 | -39.0 | -90.1 | -539.3 | -27.2 | 2 | LEAN BEAR | 681.3 |
| SUVPF Sartorius AG | $19B | 90.9 | 7.7 | 6.7 | 7.1 | 3.6 | 7 | LEAN BEAR | 8.9 |
| RSMDF ResMed Inc. | $36B | 23.9 | 24.3 | 25.3 | 26.2 | 9.9 | 7 | LEAN BEAR | -8.5 |
| BTSGU BrightSpring Health Services, Inc. Tangible Equity Unit | $12B | 41.0 | 15.5 | 10.3 | 2.2 | 19.9 | 7 | LEAN BEAR | 70.4 |
| ELAN Elanco Animal Health Incorporated | $11B | -55.9 | -3.0 | 3.7 | 3.9 | 12.0 | 5 | BEARISH | 5.5 |
| ARGX argenx SE | $55B | 31.3 | 26.0 | 50.1 | 29.8 | 162.5 | 7 | BEARISH | 7.0 |
| WXIBF WuXi Biologics (Cayman) Inc. | $26B | 31.4 | 10.6 | 16.0 | 20.7 | 16.0 | 9 | BEARISH | 23.1 |
| BAYRY Bayer AG | $48B | -25.8 | -5.5 | 6.4 | 2.0 | -1.5 | 4 | BEARISH | 59.4 |
| INCY Incyte Corporation | $23B | 14.1 | 30.7 | 82.1 | 35.0 | 26.9 | 8 | BEARISH | 26.9 |
| SOLV Solventum Corporation | $15B | 10.1 | 34.0 | 18.1 | 4.2 | -0.9 | 7 | BEARISH | 18.8 |
| IVBXF Innovent Biologics, Inc. | $20B | 97.0 | 6.9 | 67.2 | 14.5 | 35.4 | 6 | BEARISH | -5.6 |
| BMRN BioMarin Pharmaceutical Inc. | $11B | 146.9 | 1.2 | 1.4 | 4.5 | 11.2 | 4 | BEARISH | 2.2 |
| OCPNF Olympus Corporation | $12B | 24.6 | 10.6 | 12.7 | 7.9 | 7.8 | 5 | BEARISH | -9.8 |
| ALNY Alnylam Pharmaceuticals, Inc. | $30B | 37.1 | 100.7 | -152.8 | 12.7 | 95.1 | 6 | BEARISH | -50.9 |
| MDLN Medline Inc. | $30B | 38.5 | 3.2 | 4.4 | 0.8 | — | 4 | BEARISH | — |
| RVMDW Revolution Medicines, Inc. Warrant | $40B | -20.6 | -79.1 | 186.4 | — | — | 1 | BEARISH | 2279.1 |
| MRK Merck & Co., Inc. | $358B | 112.0 | 7.0 | 6.1 | -8.0 | 4.5 | 4 | BEARISH | 62.7 |
| WUXAY WuXi AppTec Co., Ltd. | $68B | 15.4 | 30.2 | 35.4 | 39.1 | 25.0 | 8 | BEARISH | 85.4 |
| TEM Tempus AI, Inc. | $12B | -48.0 | -67.4 | -19.8 | 1.5 | 50.4 | 4 | BEARISH | -22.8 |
| RVMD Revolution Medicines, Inc. | $40B | -20.6 | -79.1 | 186.4 | — | — | 1 | BEARISH | 243.7 |
| DXCM DexCom, Inc. | $29B | 30.4 | 38.5 | 42.9 | 19.0 | 15.5 | 9 | BEARISH | 10.6 |
| BNTX BioNTech SE | $22B | -11.4 | -9.3 | -18.0 | -777.3 | -8.2 | 2 | BEARISH | -17.1 |
| JAZZ Jazz Pharmaceuticals plc | $14B | 13.6 | 22.1 | 26.4 | 16.0 | 12.6 | 8 | BEARISH | 48.9 |
| MDGL Madrigal Pharmaceuticals, Inc. | $10B | -34.2 | -53.3 | -778.9 | -15.9 | 149.0 | 2 | BEARISH | 3.3 |
| INSM Insmed Incorporated | $20B | -23.1 | -87.2 | -364.8 | -3.1 | 185.8 | 5 | BEARISH | -41.7 |
| GIKLY Grifols, S.A. | $15B | 15.9 | 8.4 | 7.4 | 8.2 | -0.2 | 6 | BEARISH | -19.0 |
| SMMT Summit Therapeutics Inc. | $12B | -13.2 | -192.5 | 1714.4 | — | — | 3 | BEARISH | -22.7 |
| SBMFF Sino Biopharmaceutical Limited | $12B | 30.4 | 21.1 | 40.0 | 17.7 | 28.2 | 7 | BEARISH | -28.2 |
Profile Radar
Valuation vs Profitability
Performance Comparison
Industry Market Share
PFE vs Benchmarks
ROIC
Gross Margin
Op Margin
Net Margin
Revenue Growth
P/E Ratio
ROE
Piotroski F